Stifel analyst Brian Chin downgrades FormFactor (NASDAQ:FORM) from Buy to Hold and announces $30 price target.
Artelo Biosciences Announces Publication Of New Peer-Reviewed Research Demonstrating Protective Properties Of ART27.13 Against Muscle Degeneration Caused By Certain Cancers
Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological
